文献速递贫血与红细胞疾病

腺嘌呤碱基编辑器介导纠正常见且严重的IVS1-110(G>A)β-地中海贫血突变

Adenine base editor-mediated correction of the common and severe IVS1-110 (G>A) β-thalassemia mutation.
PubMed 文献 · Blood · 2023-01-01

β-地中海贫血由影响β-珠蛋白生成的突变引起,唯一治愈手段为异基因造血干/祖细胞移植,但受供者限制。本研究开发SpRY-ABE8e碱基编辑策略纠正IVS1-110(G>A)突变,RNA递送安全,患者造血干/祖细胞中约80%基因纠正,无危险双链DNA断裂,并在体内外恢复β-珠蛋白生成、纠正无效红系生成。

要点

  • SpRY-ABE8e碱基编辑可纠正IVS1-110(G>A)β-地中海贫血突变。
  • RNA递送安全,患者造血干/祖细胞中约80%基因纠正,无危险双链DNA断裂。
  • 在体内外恢复β-珠蛋白生成并纠正无效红系生成。

核心结论

  • 概念验证研究为开发安全有效的β-地中海贫血自体基因治疗策略铺平道路。

研究设计与样本

  • 临床前概念验证研究,使用SpRY-ABE8e碱基编辑器纠正IVS1-110(G>A)突变。
  • 在β-地中海贫血患者造血干/祖细胞中进行RNA递送碱基编辑。
  • 在造血干/祖细胞来源的红系群体中于体外和体内评估效果。

主要发现

  • RNA递送碱基编辑系统安全,患者造血干/祖细胞中约80%基因纠正,无危险双链DNA断裂。
  • 在造血干/祖细胞来源的红系群体中恢复β-珠蛋白生成。
  • 在体外和体内纠正β-地中海贫血中典型的无效红系生成。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

β-Thalassemia (BT) is one of the most common genetic diseases worldwide and is caused by mutations affecting β-globin production. The only curative treatment is allogenic hematopoietic stem/progenitor cells (HSPCs) transplantation, an approach limited by compatible donor availability and immunological complications. Therefore, transplantation of autologous, genetically-modified HSPCs is an attractive therapeutic option. However, current gene therapy strategies based on the use of lentiviral vectors are not equally effective in all patients and CRISPR/Cas9 nuclease-based strategies raise safety concerns. Thus, base editing strategies aiming to correct the genetic defect in patients' HSPCs could provide safe and effective treatment. Here, we developed a strategy to correct one of the most prevalent BT mutations (IVS1-110 [G>A]) using the SpRY-ABE8e base editor. RNA delivery of the base editing system was safe and led to ∼80% of gene correction in the HSPCs of patients with BT without causing dangerous double-strand DNA breaks. In HSPC-derived erythroid populations, this strategy was able to restore β-globin production and correct inefficient erythropoiesis typically observed in BT both in vitro and in vivo. In conclusion, this proof-of-concept study paves the way for the development of a safe and effective autologous gene therapy approach for BT.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hardouin G, Antoniou P, Martinucci P, et al. Adenine base editor-mediated correction of the common and severe IVS1-110 (G>A) β-thalassemia mutation. Blood. 2023. PMID: 36508706. doi:10.1182/blood.2022016629

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。